INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 231 filers reported holding INOVIO PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.28 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,817 | -10.2% | 17,525 | +3.1% | 0.00% | – |
| Q2 2023 | $7,591 | -80.0% | 17,001 | -63.4% | 0.00% | – |
| Q1 2023 | $38,039 | -53.5% | 46,389 | -11.5% | 0.00% | – |
| Q4 2022 | $81,806 | -1.4% | 52,440 | +8.7% | 0.00% | – |
| Q3 2022 | $83,000 | +12.2% | 48,226 | +13.4% | 0.00% | – |
| Q2 2022 | $74,000 | -65.9% | 42,530 | -29.7% | 0.00% | – |
| Q1 2022 | $217,000 | -41.8% | 60,540 | -19.1% | 0.00% | -100.0% |
| Q4 2021 | $373,000 | -27.0% | 74,797 | +4.7% | 0.00% | 0.0% |
| Q3 2021 | $511,000 | -39.6% | 71,435 | -21.7% | 0.00% | -50.0% |
| Q2 2021 | $846,000 | +16.7% | 91,265 | +16.9% | 0.00% | 0.0% |
| Q1 2021 | $725,000 | +33.8% | 78,078 | +27.4% | 0.00% | 0.0% |
| Q4 2020 | $542,000 | +1.1% | 61,273 | +32.6% | 0.00% | 0.0% |
| Q3 2020 | $536,000 | -55.6% | 46,216 | +3.2% | 0.00% | -66.7% |
| Q2 2020 | $1,206,000 | +737.5% | 44,767 | +131.7% | 0.01% | +500.0% |
| Q1 2020 | $144,000 | +27.4% | 19,319 | -43.5% | 0.00% | 0.0% |
| Q4 2019 | $113,000 | +46.8% | 34,194 | -8.5% | 0.00% | – |
| Q3 2019 | $77,000 | -30.6% | 37,368 | -1.3% | 0.00% | -100.0% |
| Q2 2019 | $111,000 | -28.8% | 37,842 | -9.6% | 0.00% | 0.0% |
| Q1 2019 | $156,000 | -4.9% | 41,840 | +1.9% | 0.00% | 0.0% |
| Q4 2018 | $164,000 | -37.9% | 41,054 | -13.5% | 0.00% | -50.0% |
| Q3 2018 | $264,000 | +36.8% | 47,458 | -3.4% | 0.00% | +100.0% |
| Q2 2018 | $193,000 | -21.5% | 49,149 | -5.8% | 0.00% | -50.0% |
| Q1 2018 | $246,000 | -2.0% | 52,160 | -14.1% | 0.00% | 0.0% |
| Q4 2017 | $251,000 | -29.9% | 60,741 | +7.7% | 0.00% | -33.3% |
| Q3 2017 | $358,000 | +3.2% | 56,417 | +27.5% | 0.00% | 0.0% |
| Q2 2017 | $347,000 | +11.2% | 44,259 | -6.2% | 0.00% | 0.0% |
| Q1 2017 | $312,000 | -24.6% | 47,168 | -20.8% | 0.00% | -40.0% |
| Q4 2016 | $414,000 | -16.0% | 59,588 | +12.6% | 0.01% | -28.6% |
| Q3 2016 | $493,000 | -14.7% | 52,918 | -15.4% | 0.01% | 0.0% |
| Q2 2016 | $578,000 | +6.6% | 62,527 | +0.5% | 0.01% | 0.0% |
| Q1 2016 | $542,000 | +17.8% | 62,217 | -9.2% | 0.01% | +16.7% |
| Q4 2015 | $460,000 | +28.5% | 68,502 | +10.7% | 0.01% | +20.0% |
| Q3 2015 | $358,000 | -33.9% | 61,857 | -6.9% | 0.01% | -37.5% |
| Q2 2015 | $542,000 | +9.9% | 66,439 | +9.9% | 0.01% | +33.3% |
| Q1 2015 | $493,000 | +1.2% | 60,437 | +14.0% | 0.01% | 0.0% |
| Q4 2014 | $487,000 | +107.2% | 53,017 | +122.1% | 0.01% | +100.0% |
| Q3 2014 | $235,000 | -25.6% | 23,872 | -18.5% | 0.00% | -25.0% |
| Q2 2014 | $316,000 | – | 29,277 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |